topiramate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2706 97240-79-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • topiramate
  • beta-D-fructopyranose sulfamate
  • epitoma
  • epitomax
  • topamac
  • topamax
  • topimax
  • topomax
  • topina
The precise mechanisms by which topiramate exerts its anticonvulsant and migraine prophylaxis effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy and migraine prophylaxis. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.
  • Molecular weight: 339.36
  • Formula: C12H21NO8S
  • CLOGP: 0.04
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 115.54
  • ALOGS: -1.70
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 9.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 19.65 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 70 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.27 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.72 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 34.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 24, 1996 FDA JANSSEN PHARMS
July 1, 2007 PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1859.48 31.23 598 7814 20436 2329237
Angle closure glaucoma 1544.31 31.23 274 8138 470 2349203
Seizure 1389.93 31.23 500 7912 23966 2325707
Toxicity to various agents 1371.48 31.23 535 7877 32219 2317454
Exposure during pregnancy 1078.22 31.23 419 7993 24800 2324873
Drug ineffective 866.39 31.23 563 7849 101061 2248612
Product substitution issue 766.44 31.23 219 8193 4850 2344823
Intentional overdose 760.43 31.23 263 8149 11058 2338615
Intentional self-injury 759.52 31.23 208 8204 3919 2345754
Myopia 729.04 31.23 132 8280 266 2349407
Drug interaction 585.66 31.23 285 8127 28878 2320795
Paraesthesia 504.40 31.23 236 8176 21852 2327821
Migraine 492.31 31.23 188 8224 10465 2339208
Metabolic acidosis 487.37 31.23 161 8251 5837 2343836
Weight decreased 482.90 31.23 248 8164 28123 2321550
Somnolence 481.48 31.23 233 8179 23252 2326421
Drug hypersensitivity 475.51 31.23 291 8121 46352 2303321
Abortion spontaneous 470.21 31.23 194 8218 13251 2336422
Overdose 461.48 31.23 215 8197 19692 2329981
Status epilepticus 423.62 31.23 118 8294 2360 2347313
Renal tubular acidosis 420.13 31.23 81 8331 260 2349413
Suicidal ideation 408.01 31.23 166 8246 10921 2338752
Cognitive disorder 407.42 31.23 137 8275 5244 2344429
Nephrolithiasis 405.55 31.23 131 8281 4412 2345261
Depression 404.97 31.23 220 8192 27912 2321761
Visual perseveration 395.52 31.23 61 8351 9 2349664
Confusional state 385.75 31.23 203 8209 24141 2325532
Headache 377.23 31.23 312 8100 79867 2269806
Off label use 372.67 31.23 299 8113 73299 2276374
Vision blurred 369.60 31.23 168 8244 14500 2335173
Epilepsy 358.62 31.23 120 8292 4519 2345154
Choroidal effusion 347.46 31.23 61 8351 93 2349580
Blindness 317.40 31.23 103 8309 3515 2346158
Dizziness 310.71 31.23 245 8167 58420 2291253
Generalised tonic-clonic seizure 299.77 31.23 109 8303 5263 2344410
Disturbance in attention 290.07 31.23 108 8304 5577 2344096
Psychotic disorder 287.62 31.23 102 8310 4577 2345096
Suicide attempt 283.31 31.23 129 8283 11153 2338520
Condition aggravated 278.54 31.23 181 8231 31798 2317875
Memory impairment 263.57 31.23 128 8284 12795 2336878
Cardio-respiratory arrest 259.71 31.23 114 8298 9032 2340641
Coma 254.30 31.23 112 8300 8944 2340729
Cardiac arrest 240.34 31.23 126 8286 14804 2334869
Drug intolerance 238.72 31.23 122 8290 13595 2336078
Respiratory arrest 225.26 31.23 92 8320 6086 2343587
Intraocular pressure increased 222.23 31.23 64 8348 1445 2348228
Product use issue 213.94 31.23 109 8303 12060 2337613
Product use in unapproved indication 213.56 31.23 106 8306 11094 2338579
Drug abuse 212.24 31.23 108 8304 11918 2337755
Decreased appetite 204.70 31.23 144 8268 28747 2320926
Hyperammonaemic encephalopathy 202.92 31.23 44 8368 285 2349388
Aphasia 199.02 31.23 79 8333 4849 2344824
Visual impairment 197.10 31.23 102 8310 11653 2338020
Insomnia 193.10 31.23 133 8279 25654 2324019
Aggression 187.27 31.23 75 8337 4711 2344962
Dysarthria 186.78 31.23 81 8331 6221 2343452
Maternal exposure during pregnancy 180.00 31.23 104 8308 14759 2334914
Visual acuity reduced 176.54 31.23 74 8338 5224 2344449
Hyperammonaemia 176.49 31.23 47 8365 785 2348888
Acidosis hyperchloraemic 171.18 31.23 31 8381 62 2349611
Drug resistance 168.01 31.23 59 8353 2565 2347108
Nausea 165.59 31.23 237 8175 111952 2237721
Speech disorder 165.55 31.23 75 8337 6389 2343284
Eye pain 165.25 31.23 69 8343 4822 2344851
Anxiety 164.31 31.23 127 8285 29232 2320441
Fatigue 161.38 31.23 203 8209 84670 2265003
Loss of consciousness 160.08 31.23 105 8307 18662 2331011
Tremor 157.99 31.23 108 8304 20553 2329120
Irritability 153.37 31.23 71 8341 6356 2343317
Multiple-drug resistance 152.94 31.23 33 8379 208 2349465
Diplopia 152.02 31.23 59 8353 3406 2346267
Amnesia 148.19 31.23 72 8340 7181 2342492
Foetal exposure during pregnancy 144.24 31.23 64 8348 5188 2344485
Alopecia 142.68 31.23 104 8308 21897 2327776
Sluggishness 141.34 31.23 41 8371 949 2348724
Petit mal epilepsy 139.44 31.23 38 8374 695 2348978
Weight increased 139.01 31.23 103 8309 22234 2327439
Maculopathy 138.60 31.23 34 8378 401 2349272
Abnormal behaviour 133.92 31.23 59 8353 4701 2344972
Pregnancy 133.23 31.23 69 8343 7880 2341793
Bradyphrenia 132.79 31.23 40 8372 1059 2348614
Vomiting 132.34 31.23 169 8243 71433 2278240
Intentional product misuse 129.94 31.23 72 8340 9417 2340256
Agitation 127.56 31.23 75 8337 10976 2338697
Myokymia 123.62 31.23 20 8392 11 2349662
Focal dyscognitive seizures 120.90 31.23 32 8380 521 2349152
Tachycardia 118.84 31.23 83 8329 16326 2333347
Myoclonus 118.64 31.23 45 8367 2438 2347235
Bezoar 117.51 31.23 26 8386 187 2349486
Palpitations 116.30 31.23 82 8330 16374 2333299
Treatment failure 116.05 31.23 61 8351 7178 2342495
Necrotising colitis 115.52 31.23 25 8387 160 2349513
Mood altered 114.24 31.23 45 8367 2701 2346972
Anorexia nervosa 114.18 31.23 22 8390 70 2349603
Sopor 113.93 31.23 50 8362 3945 2345728
Choroidal detachment 110.42 31.23 21 8391 61 2349612
Corneal oedema 109.55 31.23 27 8385 325 2349348
Visual field defect 108.29 31.23 37 8375 1479 2348194
Lethargy 108.03 31.23 62 8350 8668 2341005
Hypoaesthesia 105.52 31.23 84 8328 20131 2329542
Poisoning 102.73 31.23 42 8370 2778 2346895
Death 102.46 31.23 160 8252 81308 2268365
Acidosis 102.27 31.23 36 8376 1574 2348099
Depressed mood 101.36 31.23 50 8362 5148 2344525
Feeling abnormal 100.24 31.23 87 8325 23494 2326179
Glaucoma 100.20 31.23 38 8374 2057 2347616
Flat anterior chamber of eye 99.38 31.23 18 8394 36 2349637
Hallucination 98.50 31.23 57 8355 8091 2341582
Blindness transient 98.25 31.23 30 8382 832 2348841
Hallucination, auditory 94.97 31.23 37 8375 2155 2347518
Coma blister 94.33 31.23 16 8396 17 2349656
Eating disorder 93.55 31.23 37 8375 2244 2347429
Sedation 92.38 31.23 41 8371 3321 2346352
Encephalopathy 92.29 31.23 45 8367 4516 2345157
Depressed level of consciousness 91.40 31.23 53 8359 7551 2342122
Acute myopia 90.86 31.23 16 8396 25 2349648
Disorientation 88.98 31.23 49 8363 6323 2343350
Dysgeusia 88.73 31.23 54 8358 8405 2341268
Mania 87.71 31.23 36 8376 2404 2347269
Drug ineffective for unapproved indication 84.16 31.23 37 8375 2929 2346744
Partial seizures 84.12 31.23 27 8385 885 2348788
Hallucination, visual 84.01 31.23 37 8375 2942 2346731
Mood swings 83.87 31.23 38 8374 3231 2346442
Amenorrhoea 83.78 31.23 34 8378 2205 2347468
Ataxia 83.61 31.23 35 8377 2457 2347216
Iridocyclitis 82.54 31.23 23 8389 458 2349215
Mental disorder 82.47 31.23 40 8372 3967 2345706
Hypokalaemia 82.06 31.23 56 8356 10598 2339075
Hypotension 81.99 31.23 90 8322 32346 2317327
Balance disorder 81.70 31.23 54 8358 9693 2339980
Ciliary body disorder 81.54 31.23 14 8398 17 2349656
Mental impairment 80.96 31.23 34 8378 2406 2347267
Mydriasis 80.65 31.23 33 8379 2186 2347487
Gait disturbance 79.70 31.23 75 8337 22470 2327203
Anhidrosis 78.76 31.23 15 8397 44 2349629
Slow speech 78.62 31.23 20 8392 276 2349397
Salivary gland calculus 77.78 31.23 15 8397 48 2349625
Atrial septal defect 77.60 31.23 28 8384 1316 2348357
Obstructive airways disorder 77.01 31.23 28 8384 1345 2348328
Blood bicarbonate decreased 77.01 31.23 22 8390 481 2349192
Anger 76.76 31.23 33 8379 2474 2347199
Aura 74.97 31.23 19 8393 258 2349415
Therapeutic response unexpected 74.86 31.23 37 8375 3822 2345851
Ventricular septal defect 74.73 31.23 24 8388 788 2348885
Sleep disorder 74.73 31.23 44 8368 6445 2343228
Psychomotor hyperactivity 74.72 31.23 30 8382 1892 2347781
Myoclonic epilepsy 72.77 31.23 18 8394 220 2349453
Hypocitraturia 71.85 31.23 11 8401 1 2349672
Foetal death 71.42 31.23 29 8383 1883 2347790
Personality change 71.26 31.23 24 8388 917 2348756
Anaphylactic reaction 70.00 31.23 49 8363 9656 2340017
Cataract 67.87 31.23 40 8372 5868 2343805
Respiratory alkalosis 65.94 31.23 18 8394 331 2349342
Iris adhesions 65.89 31.23 14 8398 81 2349592
Apnoea 65.33 31.23 25 8387 1386 2348287
Tearfulness 63.51 31.23 22 8390 916 2348757
Dysmorphism 63.11 31.23 18 8394 391 2349282
Maternal drugs affecting foetus 63.10 31.23 25 8387 1522 2348151
Suicidal behaviour 63.09 31.23 19 8393 502 2349171
Oligomenorrhoea 63.08 31.23 16 8396 218 2349455
Treatment noncompliance 62.35 31.23 37 8375 5497 2344176
Paranoia 62.10 31.23 27 8385 2080 2347593
Crying 61.90 31.23 34 8378 4362 2345311
Nephrocalcinosis 60.89 31.23 15 8397 180 2349493
Mitochondrial DNULL mutation 60.88 31.23 10 8402 7 2349666
Ammonia increased 60.02 31.23 20 8392 739 2348934
Electrocardiogram QT prolonged 59.98 31.23 41 8371 7773 2341900
Respiratory failure 59.64 31.23 51 8361 13477 2336196
Blood creatine phosphokinase increased 59.59 31.23 35 8377 5101 2344572
Fanconi syndrome 59.44 31.23 15 8397 200 2349473
Medication error 58.85 31.23 37 8375 6094 2343579
Hypothermia 58.37 31.23 26 8386 2122 2347551
Dyspnoea 58.30 31.23 123 8289 78610 2271063
Propofol infusion syndrome 57.86 31.23 13 8399 101 2349572
Vertigo 57.67 31.23 43 8369 9341 2340332
Cerebral venous thrombosis 57.49 31.23 17 8395 421 2349252
Benign familial pemphigus 56.98 31.23 9 8403 3 2349670
Photophobia 56.79 31.23 26 8386 2263 2347410
Therapeutic product effect decreased 56.60 31.23 45 8367 10744 2338929
Dyskinesia 56.52 31.23 33 8379 4756 2344917
Developmental hip dysplasia 56.31 31.23 14 8398 175 2349498
Hepatic enzyme increased 56.00 31.23 43 8369 9759 2339914
Unresponsive to stimuli 55.97 31.23 33 8379 4843 2344830
Asthenia 55.82 31.23 90 8322 46836 2302837
Product administered to patient of inappropriate age 55.46 31.23 19 8393 765 2348908
Retinal detachment 55.33 31.23 21 8391 1138 2348535
Dystonia 54.68 31.23 25 8387 2169 2347504
Pain 54.58 31.23 104 8308 61753 2287920
Road traffic accident 54.34 31.23 31 8381 4277 2345396
Intellectual disability 54.06 31.23 13 8399 140 2349533
Ureterolithiasis 53.90 31.23 15 8397 297 2349376
Brain oedema 53.45 31.23 25 8387 2285 2347388
Alexia 53.33 31.23 9 8403 9 2349664
Bulimia nervosa 52.67 31.23 12 8400 100 2349573
Premature labour 52.49 31.23 24 8388 2082 2347591
Granuloma annulare 52.47 31.23 13 8399 160 2349513
Uveitis 52.02 31.23 22 8390 1583 2348090
Drug level decreased 51.48 31.23 19 8393 952 2348721
Premature baby 51.32 31.23 27 8385 3177 2346496
Necrotising enterocolitis neonatal 50.73 31.23 10 8402 37 2349636
Withdrawal syndrome 50.29 31.23 27 8385 3310 2346363
Hypokinesia 50.14 31.23 22 8390 1732 2347941
Simple partial seizures 49.75 31.23 12 8400 131 2349542
Conjunctival oedema 49.31 31.23 13 8399 208 2349465
Altered state of consciousness 49.29 31.23 28 8384 3832 2345841
Muscle twitching 49.18 31.23 25 8387 2740 2346933
Serotonin syndrome 48.79 31.23 27 8385 3513 2346160
Blepharospasm 48.46 31.23 16 8396 574 2349099
Blood potassium decreased 48.38 31.23 31 8381 5274 2344399
Shock 48.33 31.23 28 8384 3976 2345697
Granulomatous dermatitis 48.16 31.23 9 8403 23 2349650
Hepatitis 48.04 31.23 33 8379 6304 2343369
Sialoadenitis 47.62 31.23 13 8399 239 2349434
Tonic convulsion 47.62 31.23 13 8399 239 2349434
Lennox-Gastaut syndrome 47.10 31.23 9 8403 27 2349646
Abortion induced 46.79 31.23 26 8386 3410 2346263
Adverse drug reaction 46.57 31.23 36 8376 8247 2341426
Pregnancy on oral contraceptive 45.48 31.23 14 8398 399 2349274
Fall 45.02 31.23 82 8330 47017 2302656
Poisoning deliberate 44.26 31.23 18 8394 1173 2348500
Nervousness 44.07 31.23 29 8383 5160 2344513
Hypotonia 44.02 31.23 20 8392 1710 2347963
Hyperthermia 43.87 31.23 19 8393 1449 2348224
Heat stroke 43.77 31.23 11 8401 144 2349529
Delusion 43.65 31.23 21 8391 2044 2347629
Alice in wonderland syndrome 43.53 31.23 8 8404 18 2349655
Exposure via breast milk 43.43 31.23 13 8399 336 2349337
Premature delivery 42.99 31.23 24 8388 3176 2346497
Small for dates baby 42.68 31.23 15 8397 652 2349021
Blood prolactin increased 42.67 31.23 17 8395 1050 2348623
Patent ductus arteriosus 42.53 31.23 15 8397 659 2349014
Cleft lip and palate 42.07 31.23 10 8402 102 2349571
Tinnitus 41.92 31.23 28 8384 5107 2344566
Eye movement disorder 41.76 31.23 17 8395 1110 2348563
Neutropenia 41.41 31.23 52 8360 21496 2328177
Coordination abnormal 41.36 31.23 20 8392 1968 2347705
Nystagmus 41.36 31.23 17 8395 1138 2348535
Open angle glaucoma 41.22 31.23 10 8402 112 2349561
Stillbirth 40.95 31.23 18 8394 1423 2348250
Hypopnoea 40.88 31.23 13 8399 413 2349260
Self-induced vomiting 40.71 31.23 8 8404 29 2349644
Pain in extremity 40.57 31.23 74 8338 42466 2307207
Affect lability 40.30 31.23 20 8392 2082 2347591
Temperature intolerance 40.27 31.23 16 8396 981 2348692
Dry mouth 40.26 31.23 33 8379 8220 2341453
Hallucinations, mixed 40.18 31.23 14 8398 593 2349080
Impaired work ability 40.06 31.23 19 8393 1791 2347882
Lichen planus 40.01 31.23 13 8399 443 2349230
Anoxia 39.72 31.23 9 8403 73 2349600
Pruritus 39.58 31.23 74 8338 43266 2306407
Product dispensing error 39.52 31.23 21 8391 2520 2347153
Galactorrhoea 39.43 31.23 17 8395 1282 2348391
Heart rate increased 39.31 31.23 37 8375 11068 2338605
Cleft palate 39.10 31.23 11 8401 227 2349446
Alanine aminotransferase increased 39.02 31.23 41 8371 13991 2335682
Drug withdrawal convulsions 38.98 31.23 12 8400 342 2349331
Hypertension 38.85 31.23 57 8355 27304 2322369
Apathy 38.84 31.23 17 8395 1330 2348343
Thinking abnormal 38.79 31.23 19 8393 1923 2347750
Hemiparesis 38.68 31.23 23 8389 3427 2346246
Foetal growth restriction 38.19 31.23 16 8396 1124 2348549
Hypophosphataemic osteomalacia 37.71 31.23 7 8405 17 2349656
Mental status changes 37.50 31.23 27 8385 5555 2344118
Congenital hand malformation 37.42 31.23 9 8403 97 2349576
Photopsia 37.29 31.23 15 8397 950 2348723
Gene mutation 37.25 31.23 10 8402 172 2349501
Retinitis pigmentosa 36.85 31.23 8 8404 52 2349621
Exophthalmos 36.37 31.23 11 8401 295 2349378
Hypersensitivity 36.20 31.23 51 8361 23542 2326131
Rash 36.10 31.23 86 8326 59472 2290201
Calculus urinary 35.93 31.23 10 8402 198 2349475
Amino acid level increased 35.74 31.23 8 8404 61 2349612
Blood lactic acid increased 35.57 31.23 14 8398 837 2348836
Affective disorder 35.55 31.23 14 8398 838 2348835
Nodular rash 35.29 31.23 8 8404 65 2349608
Congenital anomaly 35.26 31.23 12 8400 473 2349200
Premature rupture of membranes 34.72 31.23 14 8398 892 2348781
Urinary incontinence 34.36 31.23 23 8389 4210 2345463
Chest discomfort 34.24 31.23 39 8373 14556 2335117
Change in seizure presentation 34.14 31.23 7 8405 33 2349640
Depersonalisation/derealisation disorder 34.00 31.23 10 8402 243 2349430
Myocarditis 33.86 31.23 15 8397 1208 2348465
Hyperventilation 33.79 31.23 15 8397 1214 2348459
Paralysis 33.75 31.23 17 8395 1827 2347846
Muscle spasms 33.65 31.23 47 8365 21519 2328154
Social avoidant behaviour 33.60 31.23 12 8400 547 2349126
Restless legs syndrome 33.17 31.23 18 8394 2253 2347420
Ovarian germ cell cancer stage II 33.09 31.23 5 8407 0 2349673
Exposure via ingestion 33.06 31.23 13 8399 775 2348898
Feeling jittery 33.00 31.23 17 8395 1915 2347758
Deafness 32.89 31.23 19 8393 2682 2346991
Restlessness 32.79 31.23 23 8389 4540 2345133
PCO2 decreased 32.79 31.23 10 8402 276 2349397
Bipolar disorder 32.78 31.23 15 8397 1303 2348370
Hepatic failure 32.57 31.23 25 8387 5664 2344009
Anticonvulsant drug level decreased 32.48 31.23 10 8402 285 2349388
Cardiac malposition 32.20 31.23 6 8406 15 2349658
Substance-induced psychotic disorder 31.99 31.23 10 8402 300 2349373
Acute respiratory distress syndrome 31.92 31.23 20 8392 3272 2346401
Paradoxical drug reaction 31.66 31.23 11 8401 462 2349211
Atonic seizures 31.61 31.23 8 8404 108 2349565
Dysphemia 31.43 31.23 11 8401 472 2349201

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 878.09 36.02 308 3230 20133 1723110
Drug ineffective 541.12 36.02 308 3230 63493 1679750
Angle closure glaucoma 382.93 36.02 68 3470 197 1743046
Foetal exposure during pregnancy 365.41 36.02 120 3418 6239 1737004
Heat stroke 331.14 36.02 59 3479 175 1743068
Somnolence 319.09 36.02 141 3397 16598 1726645
Status epilepticus 315.05 36.02 83 3455 1963 1741280
Completed suicide 271.27 36.02 125 3413 16187 1727056
Toxicity to various agents 250.39 36.02 143 3395 28998 1714245
Nephrolithiasis 243.80 36.02 79 3459 3913 1739330
Hyperammonaemia 241.30 36.02 59 3479 1019 1742224
Epilepsy 236.30 36.02 77 3461 3882 1739361
Product substitution issue 229.34 36.02 72 3466 3214 1740029
Myopia 226.92 36.02 42 3496 163 1743080
Metabolic acidosis 220.38 36.02 79 3459 5323 1737920
Sedation 218.32 36.02 70 3468 3347 1739896
Off label use 215.83 36.02 144 3394 38427 1704816
Drug interaction 213.00 36.02 127 3411 27831 1715412
Encephalopathy 196.31 36.02 69 3469 4383 1738860
Cognitive disorder 186.67 36.02 66 3472 4264 1738979
Aggression 182.42 36.02 77 3461 8038 1735205
Ataxia 178.57 36.02 55 3483 2298 1740945
Premature baby 162.47 36.02 54 3484 2888 1740355
Hypospadias 161.97 36.02 38 3500 544 1742699
Weight decreased 159.19 36.02 98 3440 22655 1720588
Product use issue 158.88 36.02 71 3467 8500 1734743
Drug resistance 149.75 36.02 52 3486 3178 1740065
Hyperthermia 147.44 36.02 44 3494 1647 1741596
Intentional overdose 146.82 36.02 65 3473 7605 1735638
Headache 142.34 36.02 107 3431 34269 1708974
Confusional state 139.55 36.02 88 3450 21190 1722053
Intentional self-injury 139.38 36.02 47 3491 2626 1740617
Generalised tonic-clonic seizure 134.69 36.02 51 3487 3995 1739248
Condition aggravated 130.04 36.02 84 3454 21066 1722177
Migraine 129.89 36.02 43 3495 2268 1740975
Abnormal behaviour 128.64 36.02 56 3482 6286 1736957
Decreased appetite 123.14 36.02 85 3453 23786 1719457
Memory impairment 122.77 36.02 55 3483 6608 1736635
Disturbance in attention 121.80 36.02 48 3490 4186 1739057
Overdose 116.79 36.02 72 3466 16629 1726614
Hypothermia 116.42 36.02 37 3501 1711 1741532
Choroidal effusion 110.99 36.02 20 3518 64 1743179
Infantile spasms 110.80 36.02 21 3517 95 1743148
Renal tubular acidosis 109.98 36.02 25 3513 308 1742935
Anhidrosis 109.62 36.02 18 3520 26 1743217
Suicide attempt 108.18 36.02 52 3486 7329 1735914
Multiple-drug resistance 106.32 36.02 24 3514 286 1742957
Product use in unapproved indication 101.80 36.02 54 3484 9368 1733875
Partial seizures 100.51 36.02 27 3511 684 1742559
Psychotic disorder 100.39 36.02 44 3494 5012 1738231
Hyperammonaemic encephalopathy 96.13 36.02 23 3515 359 1742884
Cleft lip 95.23 36.02 18 3520 80 1743163
Gait disturbance 94.60 36.02 57 3481 12613 1730630
Tremor 92.71 36.02 57 3481 13074 1730169
Exposure during pregnancy 91.86 36.02 35 3503 2782 1740461
Hypotonia 91.35 36.02 30 3508 1540 1741703
Ammonia increased 91.09 36.02 26 3512 828 1742415
Atrial septal defect 87.34 36.02 28 3510 1330 1741913
Suicidal ideation 86.89 36.02 47 3491 8471 1734772
Dysarthria 86.08 36.02 40 3498 5219 1738024
Small for dates baby 85.78 36.02 23 3515 578 1742665
Low birth weight baby 85.68 36.02 25 3513 862 1742381
Vision blurred 81.82 36.02 45 3493 8378 1734865
Flat anterior chamber of eye 81.12 36.02 14 3524 32 1743211
Agitation 80.72 36.02 49 3489 10977 1732266
Speech disorder 78.82 36.02 36 3502 4512 1738731
Drug abuse 78.19 36.02 52 3486 13637 1729606
Acidosis hyperchloraemic 76.94 36.02 14 3524 48 1743195
Paraesthesia 75.35 36.02 46 3492 10405 1732838
Mood altered 75.11 36.02 28 3510 2094 1741149
Drug reaction with eosinophilia and systemic symptoms 75.09 36.02 36 3502 5034 1738209
Sudden unexplained death in epilepsy 71.72 36.02 15 3523 121 1743122
Lethargy 71.46 36.02 39 3499 7145 1736098
Coma 71.07 36.02 39 3499 7223 1736020
Sopor 69.34 36.02 26 3512 1975 1741268
Irritability 69.16 36.02 35 3503 5497 1737746
Maculopathy 69.08 36.02 17 3521 300 1742943
Depression 66.74 36.02 51 3487 16618 1726625
Cardiac arrest 66.56 36.02 50 3488 15880 1727363
Product administered to patient of inappropriate age 65.68 36.02 20 3518 800 1742443
Depressed mood 65.56 36.02 28 3510 2988 1740255
Developmental delay 65.54 36.02 18 3520 496 1742747
Medication error 65.17 36.02 32 3506 4711 1738532
Fanconi syndrome 62.89 36.02 16 3522 325 1742918
Blood homocysteine increased 62.15 36.02 12 3526 61 1743182
Depressed level of consciousness 60.65 36.02 34 3504 6558 1736685
Dysmorphism 60.48 36.02 16 3522 381 1742862
Multiple drug therapy 59.52 36.02 11 3527 42 1743201
Delusion of replacement 58.20 36.02 10 3528 22 1743221
Microcephaly 58.19 36.02 13 3525 147 1743096
Bradycardia 57.67 36.02 39 3499 10495 1732748
Congenital hand malformation 57.24 36.02 12 3526 98 1743145
Drug ineffective for unapproved indication 57.01 36.02 22 3516 1807 1741436
Balance disorder 56.26 36.02 31 3507 5781 1737462
Retinal vein occlusion 53.94 36.02 15 3523 433 1742810
Hyperchloraemia 53.47 36.02 11 3527 81 1743162
Visual acuity reduced 52.71 36.02 26 3512 3862 1739381
Treatment failure 52.54 36.02 27 3511 4374 1738869
Foetal growth restriction 51.87 36.02 16 3522 668 1742575
Supraventricular tachycardia 51.82 36.02 20 3518 1643 1741600
Drug withdrawal syndrome neonatal 51.78 36.02 16 3522 672 1742571
Nasal septum disorder 51.43 36.02 9 3529 23 1743220
Petit mal epilepsy 50.42 36.02 15 3523 553 1742690
Talipes 50.05 36.02 14 3524 413 1742830
Autonomic nervous system imbalance 50.05 36.02 14 3524 413 1742830
Focal dyscognitive seizures 48.84 36.02 13 3525 317 1742926
Fall 48.77 36.02 53 3485 27161 1716082
Cleft lip and palate 48.26 36.02 11 3527 137 1743106
Glaucoma 48.03 36.02 17 3521 1094 1742149
Maternal drugs affecting foetus 47.16 36.02 17 3521 1154 1742089
Disorientation 47.04 36.02 27 3511 5442 1737801
Priapism 47.02 36.02 18 3520 1446 1741797
Fatigue 46.75 36.02 71 3467 50710 1692533
Hallucination, visual 46.41 36.02 21 3517 2571 1740672
Neuromyopathy 45.88 36.02 11 3527 173 1743070
Myoclonus 45.59 36.02 20 3518 2275 1740968
Drug hypersensitivity 45.09 36.02 39 3499 15096 1728147
Acid-base balance disorder mixed 44.54 36.02 7 3531 6 1743237
Therapeutic product effect incomplete 44.47 36.02 26 3512 5422 1737821
Bradyphrenia 43.95 36.02 14 3524 650 1742593
Neonatal respiratory depression 43.78 36.02 9 3529 66 1743177
Acidosis 43.09 36.02 17 3521 1480 1741763
Unresponsive to stimuli 42.90 36.02 24 3514 4605 1738638
Nystagmus 42.70 36.02 15 3523 944 1742299
Insomnia 42.65 36.02 39 3499 16237 1727006
Unmasking of previously unidentified disease 42.35 36.02 9 3529 79 1743164
Intentional product misuse 42.07 36.02 28 3510 7330 1735913
Hypohidrosis 42.05 36.02 8 3530 37 1743206
Apathy 41.86 36.02 16 3522 1280 1741963
Madarosis 41.57 36.02 9 3529 87 1743156
Non-24-hour sleep-wake disorder 41.53 36.02 7 3531 13 1743230
Pyloric stenosis 41.43 36.02 10 3528 162 1743081
Optic atrophy 41.37 36.02 11 3527 267 1742976
Hyperventilation 41.20 36.02 13 3525 585 1742658
Bicuspid aortic valve 40.59 36.02 9 3529 98 1743145
Psychomotor retardation 40.42 36.02 12 3526 439 1742804
Anxiety 40.28 36.02 37 3501 15490 1727753
Hippocampal sclerosis 40.25 36.02 7 3531 17 1743226
Eye pain 38.94 36.02 18 3520 2313 1740930
Affective disorder 38.87 36.02 13 3525 705 1742538
Hyperexplexia 38.83 36.02 6 3532 4 1743239
Developmental hip dysplasia 38.76 36.02 8 3530 60 1743183
Rash 38.28 36.02 56 3482 38637 1704606
Therapeutic response unexpected 38.27 36.02 18 3520 2406 1740837
Dry mouth 38.21 36.02 21 3517 3892 1739351
Erectile dysfunction 38.13 36.02 22 3516 4475 1738768
Dizziness 37.31 36.02 52 3486 34309 1708934
Therapeutic product cross-reactivity 37.25 36.02 10 3528 252 1742991
Perseveration 37.23 36.02 7 3531 30 1743213
Mental status changes 36.87 36.02 24 3514 6051 1737192
Nausea 36.77 36.02 64 3474 51132 1692111
Amnesia 36.41 36.02 22 3516 4869 1738374

Pharmacologic Action:

SourceCodeDescription
ATC N03AX11 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
CHEBI has role CHEBI:35623 anticonvulsant
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D007004 Hypoglycemic Agents
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
FDA MoA N0000185506 Cytochrome P450 3A4 Inducers
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Lennox-Gastaut syndrome indication 230418006
Tonic-clonic epilepsy indication 352818000 DOID:7725
Epilepsy characterized by intractable complex partial seizures indication 442481002
Simple partial seizure indication 117891000119100
Migraine Prevention indication
Alcoholism off-label use 7200002
Essential tremor off-label use 609558009 DOID:4990
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Reduced visual acuity contraindication 13164000
Mood swings contraindication 18963009
Secondary angle-closure glaucoma contraindication 21571006
Depressive disorder contraindication 35489007
Metabolic acidosis contraindication 59455009
Diarrhea contraindication 62315008
Fatigue contraindication 84229001
Kidney disease contraindication 90708001 DOID:557
Paresthesia contraindication 91019004
Kidney stone contraindication 95570007
Diminished sweating contraindication 111980002
Disease of liver contraindication 235856003 DOID:409
Drowsy contraindication 271782001
Pregnancy, function contraindication 289908002
Fever contraindication 386661006
Impaired cognition contraindication 386806002
Memory impairment contraindication 386807006
Dizziness contraindication 404640003
Concentration Difficulty contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.6 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7056890 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7553818 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7659256 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7674776 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7056890 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7553818 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7659256 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7674776 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7056890 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7553818 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7659256 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7674776 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7056890 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7553818 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7659256 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7674776 June 14, 2020 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 10314790 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 10314790 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298580 Nov. 16, 2027 TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298580 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8663683 Nov. 16, 2027 TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8663683 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8877248 Nov. 16, 2027 TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8877248 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8889191 Nov. 16, 2027 TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8889191 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8992989 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8992989 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9549940 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9549940 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9555004 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9555004 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9622983 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9622983 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 10314790 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 10314790 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298580 Nov. 16, 2027 TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298580 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8663683 Nov. 16, 2027 TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8663683 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8877248 Nov. 16, 2027 TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8877248 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8889191 Nov. 16, 2027 TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8889191 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8992989 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8992989 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9549940 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9549940 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9555004 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9555004 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9622983 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9622983 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 10314790 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 10314790 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298580 Nov. 16, 2027 TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298580 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8663683 Nov. 16, 2027 TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8663683 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8877248 Nov. 16, 2027 TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8877248 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8889191 Nov. 16, 2027 TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8889191 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8992989 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8992989 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9549940 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9549940 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9555004 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9555004 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9622983 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9622983 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 10314790 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 10314790 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298580 Nov. 16, 2027 TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298580 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8663683 Nov. 16, 2027 TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8663683 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8877248 Nov. 16, 2027 TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8877248 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8889191 Nov. 16, 2027 TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8889191 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8992989 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8992989 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9549940 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9549940 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9555004 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9555004 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9622983 Nov. 16, 2027 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 9622983 Nov. 16, 2027 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298576 April 4, 2028 TREATMENT OF EPILEPSY
100MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298576 April 4, 2028 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298576 April 4, 2028 TREATMENT OF EPILEPSY
200MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298576 April 4, 2028 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298576 April 4, 2028 TREATMENT OF EPILEPSY
25MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298576 April 4, 2028 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298576 April 4, 2028 TREATMENT OF EPILEPSY
50MG TROKENDI XR SUPERNUS PHARMS N201635 Aug. 16, 2013 RX CAPSULE, EXTENDED RELEASE ORAL 8298576 April 4, 2028 USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
100MG QUDEXY XR UPSHER SMITH LABS N205122 March 11, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 10363224 March 19, 2033 TREATMENT OF SEIZURES
150MG QUDEXY XR UPSHER SMITH LABS N205122 March 11, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 10363224 March 19, 2033 TREATMENT OF SEIZURES
200MG QUDEXY XR UPSHER SMITH LABS N205122 March 11, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 10363224 March 19, 2033 TREATMENT OF SEIZURES
25MG QUDEXY XR UPSHER SMITH LABS N205122 March 11, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 10363224 March 19, 2033 TREATMENT OF SEIZURES
50MG QUDEXY XR UPSHER SMITH LABS N205122 March 11, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 10363224 March 19, 2033 TREATMENT OF SEIZURES

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE MODULATOR WOMBAT-PK CHEMBL
Carbonic anhydrase 4 Enzyme INHIBITOR Ki 5.31 CHEMBL CHEMBL
Carbonic anhydrase 2 Enzyme INHIBITOR Ki 8.30 CHEMBL CHEMBL
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Glutamate receptor ionotropic AMPA Ion channel ANTAGONIST CHEMBL CHEMBL
Glutamate receptor ionotropic kainate Ion channel ANTAGONIST CHEMBL CHEMBL
Sodium channel protein type 1 subunit alpha Ion channel BLOCKER DRUGBANK CHEMBL
Carbonic anhydrase V Enzyme Ki 7.60 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Kd 7.60 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 5.84 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 9.06 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.24 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 6.60 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 7.52 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 7.35 CHEMBL
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
Carbonic anhydrase 12 Enzyme Ki 8.42 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 7.33 CHEMBL
Alpha carbonic anhydrase Unclassified Ki 7.54 CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme Ki 5.52 CHEMBL
Astrosclerin-3 Unclassified Ki 7.42 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 6.21 CHEMBL
Carbonic anhydrase Unclassified Ki 6.44 CHEMBL
Delta carbonic anhydrase Unclassified Ki 6.41 CHEMBL
Carbonic anhydrase Enzyme Ki 6.96 CHEMBL
Carbonic anhydrase Enzyme Ki 6.76 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.11 CHEMBL
Carbonic anhydrase 2 Enzyme IC50 5.85 CHEMBL
Carbonic anhydrase Enzyme Ki 8 CHEMBL
Carbonic anhydrase Enzyme Ki 6.92 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.32 CHEMBL
Sodium channel protein type 2 subunit alpha Ion channel IC50 4.01 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 7.27 CHEMBL
Carbonic anhydrase Enzyme Ki 6.96 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 7.33 CHEMBL
Carbonic anhydrase 2 Unclassified Ki 6.43 CHEMBL
Carbonic anhydrase Enzyme Ki 4.63 CHEMBL

External reference:

IDSource
D000077236 MESH_DESCRIPTOR_UI
4021026 VUID
N0000148493 NUI
C0076829 UMLSCUI
D00537 KEGG_DRUG
0H73WJJ391 UNII
6099 INN_ID
108400009 SNOMEDCT_US
4021026 VANDF
162273 MMSL
005453 NDDF
d04115 MMSL
5601 MMSL
38404 RXNORM
386844006 SNOMEDCT_US
CHEMBL220492 ChEMBL_ID
DB00273 DRUGBANK_ID
TOR PDB_CHEM_ID
CHEBI:63631 CHEBI
5284627 PUBCHEM_CID
6849 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7335 CAPSULE, COATED PELLETS 15 mg ORAL ANDA 17 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7336 CAPSULE, COATED PELLETS 25 mg ORAL ANDA 17 sections
QUDEXY HUMAN PRESCRIPTION DRUG LABEL 1 0245-1071 CAPSULE, EXTENDED RELEASE 25 mg ORAL NDA 18 sections
QUDEXY HUMAN PRESCRIPTION DRUG LABEL 1 0245-1072 CAPSULE, EXTENDED RELEASE 50 mg ORAL NDA 18 sections
QUDEXY HUMAN PRESCRIPTION DRUG LABEL 1 0245-1073 CAPSULE, EXTENDED RELEASE 200 mg ORAL NDA 18 sections
QUDEXY HUMAN PRESCRIPTION DRUG LABEL 1 0245-1074 CAPSULE, EXTENDED RELEASE 100 mg ORAL NDA 18 sections
QUDEXY HUMAN PRESCRIPTION DRUG LABEL 1 0245-1075 CAPSULE, EXTENDED RELEASE 150 mg ORAL NDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0615-7562 TABLET, FILM COATED 25 mg ORAL ANDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0615-7563 TABLET, FILM COATED 50 mg ORAL ANDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0615-7564 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0615-7565 TABLET, FILM COATED 200 mg ORAL ANDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8138 TABLET, FILM COATED 25 mg ORAL ANDA 17 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8139 TABLET, FILM COATED 50 mg ORAL ANDA 17 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8140 TABLET, FILM COATED 100 mg ORAL ANDA 17 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1071 CAPSULE, EXTENDED RELEASE 25 mg ORAL NDA authorized generic 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1072 CAPSULE, EXTENDED RELEASE 50 mg ORAL NDA authorized generic 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1073 CAPSULE, EXTENDED RELEASE 200 mg ORAL NDA authorized generic 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1074 CAPSULE, EXTENDED RELEASE 100 mg ORAL NDA authorized generic 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1075 CAPSULE, EXTENDED RELEASE 150 mg ORAL NDA authorized generic 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 10544-489 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 10544-628 TABLET 25 mg ORAL ANDA 19 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 10544-847 TABLET, FILM COATED 50 mg ORAL ANDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 12634-083 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 12634-452 TABLET 25 mg ORAL ANDA 18 sections
Topiramate HUMAN PRESCRIPTION DRUG LABEL 1 12634-453 TABLET 50 mg ORAL ANDA 18 sections
TOPIRAMATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-034 TABLET 200 mg ORAL ANDA 17 sections
TOPIRAMATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-817 TABLET 100 mg ORAL ANDA 20 sections
TOPIRAMATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-824 TABLET 25 mg ORAL ANDA 20 sections
TOPIRAMATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-825 TABLET 50 mg ORAL ANDA 20 sections
Trokendi XR HUMAN PRESCRIPTION DRUG LABEL 1 17772-101 CAPSULE, EXTENDED RELEASE 25 mg ORAL NDA 18 sections